Tillie-Leblond I, Tonnel A-B
Department of Pulmonology and Immuno-Allergology, University Hospital of Lille, Lille, France.
Allergy. 2005 Aug;60(8):1004-13. doi: 10.1111/j.1398-9995.2005.00887.x.
Allergic bronchopulmonary aspergillosis (ABPA) occurs in nonimmunocompromised patients and belongs to the hypersensitivity disorders induced by Aspergillus. Genetic factors and activation of bronchial epithelial cells in asthma or cystic fibrosis are responsible for the development of a CD(4)+Th2 lymphocyte activation and IgE, IgG and IgA-AF antibodies production. The diagnosis of ABPA is based on the presence of a combination of clinical, biological and radiological criteria. The severity of the disease is related to corticosteroid-dependant asthma or/and diffuse bronchiectasis with fibrosis. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and itraconazole is now recommended and validated at a dose of 200 mg/day for a duration of 16 weeks.
变应性支气管肺曲霉病（ABPA）发生于非免疫功能低下患者，属于由曲霉引起的超敏反应性疾病。哮喘或囊性纤维化患者的遗传因素及支气管上皮细胞激活导致CD(4)+Th2淋巴细胞活化及IgE、IgG和IgA-AF抗体产生。ABPA的诊断基于临床、生物学和放射学标准的综合存在情况。疾病的严重程度与依赖皮质类固醇的哮喘或/和伴有纤维化的弥漫性支气管扩张有关。治疗在急性期或病情加重时基于口服皮质类固醇6 - 8周，目前推荐并验证使用伊曲康唑，剂量为200mg/天，持续16周。
